Scholarlink

Background <p>Mushrooms have long been recognized as rich sources of bioactive compounds. Among edible mushrooms, <i>Agaricus bisporus</i> and <i>Lentinula edodes</i> are highly valued for their nutritional and medicinal profiles. However, the therapeutic potential of their aqueous extracts, particularly those from mushrooms cultivated under Sri Lanka’s distinct agroclimatic conditions, remains underexplored, requiring a detailed investigation.</p> Methods <p>Commercially cultivated <i>A. bisporus</i> and <i>L. edodes</i> mushrooms were processed into powders, and aqueous extracts were prepared, followed by freeze-drying. The antioxidant activity of the extracts was evaluated via DPPH, FRAP, nitric oxide inhibition, and superoxide scavenging assays. Cytotoxicity was tested in rhabdomyosarcoma (RD) cancer cell lines via a MTT assay, and morphological changes were examined microscopically. The antidiabetic activity was determined via an antiglycation assay, whereas the antibacterial efficacy was tested against six bacterial strains via the disc diffusion and agar dilution methods.</p> Results <p><i>L. edodes</i> extract showed higher antioxidant activity compared to <i>A. bisporus</i>, with lower EC₅₀ values for DPPH (0.20 ± 0.01&#xa0;mg/mL vs. 0.24 ± 0.01&#xa0;mg/mL), superoxide (0.42 ± 0.01&#xa0;mg/mL vs. 1.38 ± 0.08&#xa0;mg/mL), and nitric oxide inhibition (3.26 ± 0.01&#xa0;mg/mL vs. 8.79 ± 0.07&#xa0;mg/mL), along with higher FRAP values (51.56 ± 0.74 vs. 23.83 ± 1.25&#xa0;mg Trolox·g⁻¹ extract). In cytotoxicity assays, <i>L. edodes</i> exhibited stronger anticancer activity against RD cells (IC₅₀ = 1.75 ± 0.01&#xa0;mg/mL) than <i>A. bisporus</i> (IC₅₀ = 12.03 ± 0.24&#xa0;mg/mL). <i>L. edodes</i> extract also had higher antiglycation activity (EC₅₀ = 131.62 ± 0.63&#xa0;µg/mL) than <i>A. bisporus</i> extract (EC₅₀ = 339.72 ± 1.89&#xa0;µg/mL) Antibacterial assays revealed that <i>L. edodes</i> inhibited all six tested bacterial strains, whereas <i>A. bisporus</i> showed no inhibition.</p> Conclusions <p>Both <i>A. bisporus</i> and <i>L. edodes</i> extracts showed marked antioxidant, anticancer, and antidiabetic activities. Compared to <i>A. bisporus</i>, <i>L. edodes</i> demonstrated higher activities and showed antibacterial effects. These findings underscore the potential of both mushrooms as valuable sources for therapeutic and nutraceutical development.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative study on the therapeutic potential of aqueous extracts from commercially cultivated Agaricus bisporus and Lentinula edodes in Sri Lanka: antioxidant, anticancer, antidiabetic, and antibacterial properties

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • G. V. S. Pabasara,
  • M. D.M. Fernando,
  • W. K. S. M. Abeysekera,
  • L. V. C. Liyanapathirana

摘要

Background

Mushrooms have long been recognized as rich sources of bioactive compounds. Among edible mushrooms, Agaricus bisporus and Lentinula edodes are highly valued for their nutritional and medicinal profiles. However, the therapeutic potential of their aqueous extracts, particularly those from mushrooms cultivated under Sri Lanka’s distinct agroclimatic conditions, remains underexplored, requiring a detailed investigation.

Methods

Commercially cultivated A. bisporus and L. edodes mushrooms were processed into powders, and aqueous extracts were prepared, followed by freeze-drying. The antioxidant activity of the extracts was evaluated via DPPH, FRAP, nitric oxide inhibition, and superoxide scavenging assays. Cytotoxicity was tested in rhabdomyosarcoma (RD) cancer cell lines via a MTT assay, and morphological changes were examined microscopically. The antidiabetic activity was determined via an antiglycation assay, whereas the antibacterial efficacy was tested against six bacterial strains via the disc diffusion and agar dilution methods.

Results

L. edodes extract showed higher antioxidant activity compared to A. bisporus, with lower EC₅₀ values for DPPH (0.20 ± 0.01 mg/mL vs. 0.24 ± 0.01 mg/mL), superoxide (0.42 ± 0.01 mg/mL vs. 1.38 ± 0.08 mg/mL), and nitric oxide inhibition (3.26 ± 0.01 mg/mL vs. 8.79 ± 0.07 mg/mL), along with higher FRAP values (51.56 ± 0.74 vs. 23.83 ± 1.25 mg Trolox·g⁻¹ extract). In cytotoxicity assays, L. edodes exhibited stronger anticancer activity against RD cells (IC₅₀ = 1.75 ± 0.01 mg/mL) than A. bisporus (IC₅₀ = 12.03 ± 0.24 mg/mL). L. edodes extract also had higher antiglycation activity (EC₅₀ = 131.62 ± 0.63 µg/mL) than A. bisporus extract (EC₅₀ = 339.72 ± 1.89 µg/mL) Antibacterial assays revealed that L. edodes inhibited all six tested bacterial strains, whereas A. bisporus showed no inhibition.

Conclusions

Both A. bisporus and L. edodes extracts showed marked antioxidant, anticancer, and antidiabetic activities. Compared to A. bisporus, L. edodes demonstrated higher activities and showed antibacterial effects. These findings underscore the potential of both mushrooms as valuable sources for therapeutic and nutraceutical development.

Clinical trial number

Not applicable.